Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (251-260 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|January 20, 2023
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangementsMaria Siddiqui, Sergej Konoplev, Ghayas Issa, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Blood|April 7, 2022
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemiaMehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Journal of Hematology & Oncology|November 16, 2024
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosisSamuel Urrutia, Hagop M Kantarjian, Farhad Ravandi-Kashani, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Pageof 44

Showing results (251-260 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|January 20, 2023
Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangementsMaria Siddiqui, Sergej Konoplev, Ghayas Issa, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Blood Advances|December 22, 2020
Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLNicholas J Short, Hind Rafei, Naval Daver, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Blood|April 7, 2022
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemiaMehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Journal of Hematology & Oncology|November 16, 2024
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosisSamuel Urrutia, Hagop M Kantarjian, Farhad Ravandi-Kashani, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Pageof 44